• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The International journal of pharmacy practice >Barriers to pharmacist prescribing: a scoping review comparing the UK, New Zealand, Canadian and Australian experiences
【24h】

Barriers to pharmacist prescribing: a scoping review comparing the UK, New Zealand, Canadian and Australian experiences

机译：药剂师处方的障碍：一个衡量英国，新西兰，加拿大和澳大利亚经验的范围审查

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Abstract Objectives Non‐medical prescribers, including pharmacists, have been found to achieve comparable clinical outcomes with doctors for certain health conditions. Legislation supporting pharmacist prescribing (PP) has been implemented in the United Kingdom (UK), Canada and New Zealand (NZ); however, to date, Australian pharmacists have not been extended prescribing rights. The purpose of this review was to describe the barriers to PP found in the literature from the UK, Canada, NZ and Australia, and examine the implications of these for the development of PP in Australia. Methods We conducted a scoping review, which included peer‐reviewed and grey literature, and consultation with stakeholders. Sources – Scopus, PubMed and CINAHL; Google Scholar, OpenGrey and organisational websites from January 2003 to March 2018 in the UK, Canada, NZ and Australia. Inclusion criteria – articles published in English, related to implementation of PP and articulated barriers to PP. Key findings Of 863 unique records, 120 were reviewed and 64 articles were eligible for inclusion. Three key themes emerged: (1) Socio‐political context, (2) Resourcing issues and (3) Prescriber competence. The most common barriers were inadequate training regarding diagnostic knowledge and skills, inadequate support from authorities and stakeholders, and insufficient funding/reimbursement. Conclusions If implementation of PP is to occur, attention needs to be focused on addressing identified barriers to PP implementation, including fostering a favourable socio‐political context and prescriber competence. As such, a concerted effort is required to develop clear policy pathways, including targeted training courses, raising stakeholder recognition of PP and identifying specific funding, infrastructure and resourcing needs to ensure the smooth integration of pharmacist prescribers within interprofessional clinical teams.
机译：摘要目的，包括药剂师在内的非医疗公务员，已被发现在某些健康状况下与医生实现了可比的临床结果。支持药剂师处方（PP）的立法已在英国（英国），加拿大和新西兰（NZ）实施;但是，迄今为止，澳大利亚药剂师尚未延长处方权利。本评价的目的是描述来自英国，加拿大，新西兰和澳大利亚的文学中PP的障碍，并研究了这些对澳大利亚PP的发展的影响。方法我们进行了一个范围的评论，其中包括同行评审和灰色文学，以及与利益相关者的协商。来源 - Scopus，PubMed和Cinahl;谷歌学者，2003年1月至2018年3月在英国，加拿大，NZ和澳大利亚的谷歌和组织网站。纳入标准 - 用英文发表的文章，与PP的实施相关，并铰接式屏障对PP。 863个独特记录的主要结果进行了审查，64篇文章有资格包涵式。出现了三个关键主题：（1）社会 - 政治背景，（2）资源问题和（3）售价能力。最常见的障碍是有关诊断知识和技能的培训不足，当局和利益攸关方的支持不足，资金/报销不足/偿还。结论如果发生PP的实施，需要重点关注对PP实施的确定障碍，包括促进有利的社会 - 政治背景和处方者竞争力。因此，需要一致的努力来制定明确的政策途径，包括有针对性的培训课程，提高利益相关者认可，并确定特定资金，基础设施和资源需要确保药剂师公务员在侦听临床团队中的顺利整合。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号